Plasma cell neoplasms

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-48

Palumbo A; Avet-Loiseau H; Oliva S; Lokhorst HM et al.Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015; 33(26):2863-9

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391-2405.

Mikulasova A, Wardell CP, Murison A et al .: The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica 102: 1617-1625, 2017. DOI: 10.3324 / haematol.2017.163766

Bergsagel PL, Chesi MV Molecular classification and risk stratification of myeloma. Hematol Oncol 31 Suppl 1: 38-41, 2013. DOI: 10.1002 / hon. 2065

Rajkumar SV: Updated Diagnostic Criteria and Staging System for Multiple Myeloma. Am Sco Clin Oncol Educ Book 35: e418-e423, 2016. DOI: 10.1200 / EDBK _159009

Kortüm KM, Mai EK, Hanafiah NH et al .: Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood 128: 1226-1233, 2016. DOI: 10.1182 / blood-2016-02-698092

Mitchell JS, Li N, Weinholf N et al .: Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun 7: 2050, 2016. DOI: 10.1038 / ncomms12050

Landgren O, Linet MS, McMaster ML et .: Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: A population-based case-control study. International Journal of Cancer 118: 3095-3098, 2006. DOI: 10.1002 / ijc.21745

Wallin A, Larsson SC: Body mass index and risk of multiple myeloma: A meta-analysis of prospective studies. Eur J Cancer 47: 1606-1615, 2011. DOI: 10.1016 / j.ejca.2011.01.020

Weiss BM, Abadie J, Verma P et al .: A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113: 5418-5422, 2009. DOI: 10.1182 / blood-2008-12-195008

Landgren O, Kyle RA, Pfeiffer RM et al .: Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study. Blood 113: 5412-5417, 2009. DOI: 10.1182 / blood-2008-12-194241

Eisele L, Dürig J, Hüttmann A et al .: Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Annals of Hematology 91: 243-248, 2012. DOI: 10.1007 / s00277-011-1293-1

Zingone A, Kuehl WM: Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Seminars in Hematology 48: 4-12, 2011. DOI: 10.1053 / j.seminhematol.2010.11.003

Dispenzieri A, Katzmann JA, Kyle RA et al .: Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 375: 1721-1728, 2010. DOI: 10.1016 / S0140-6736 (10) 60482-5

Kristinsson SY, Björkholm M, Andersson TM et al .: Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined signficance: a population-based study. Haematologica 94: 1714-1720, 2009. DOI: 10.3324 / haematol.2009.010066

Ludwig H, Hajek R, Tothova E et al .: Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 113: 3435-3442, 2009. DOI: 10.1182 / blood-2008-07-169565

Dimopoulos MA, Cheung MC, Roussel M, et al .: Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica 101: 363-370, 2016. DOI: 10.3324 / haematol.2015.133629

Dimopoulos MA, Roussou M, Gavriatopoulou M et al .: Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol 91: 499-502, 2016. DOI: 10.1002 / ajh.24335

Dimopoulos MA, Sonneveld P, Leung N et al .: International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol 34: 1544-1557, 2016. DOI: 10.1200 / JCO.2015.65.0044

St Bernard R, Chodirker L, Masih-Khan E, Jiang H, Franke N, Kukreti V, Tiedemann R, Trudel S, Reece D, Chen CI. Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure. Bone Marrow Transplant 50: 95-99, 2015. DOI: 10.1038 / bmt.2014.226

Zannetti BA, Zamagni E, Santostefano M et al .: Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment. Am J Hematol 90: 647-652, 2015. DOI: 10.1002 / ajh.24035

Bridoux F, Carron PL. Pegourie B et al .: Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial. JAMA 318: 2099-2110, 2017. DOI: 10.1001 / jama.2017.17924

Lokhorst HM, van der Holt B, Cornelissen JJ et al .: Reduced relapse rate in upfront tandem autologous / reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival. Haematologica 100: e508-510, 2015. DOI: 10.3324 / haematol.2015.128728

Richardson PG, Hungria VT, Yoon SS et al .: Panobinostat plus bortezomib and dexamethasone in relapsed / relapsed and refractory myeloma: outcomes by prior treatment. Blood Dec 2 Epub ahead of print. DOI: 10.1182 / blood-2015-09-665018

San Miguel J, Weisel K, Moreau P et al .: Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomized, open-label, phase 3 trial. Lancet Oncol 14: 1055-1066, 2013. DOI: 10.1016 / S1470-2045 (13) 70380-2

Palumbo A, Chanan-Khan A, Weisel K et al .: Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 375: 754-766, 2016. DOI: 10.1056 / NEJMoa1606038

Dimopoulos M, Oriol H, Nahi H et al .: Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 375: 1319-1331, 2016. DOI: 10.1056 / NEJMoa1607751

Lonial S, Dimopoulos MA, Palumbo A et al .: Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 373: 621-631, 2015. DOI: 10.1056 / NEJMoa1505654

NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Available from: http:// www.nccn.org/professionals/physicians_gls/pdf/myelomapdf. Version 2.2020-October 9, 2019.